Merck Nears Completion of Singapore Expansion
MSD Technology Singapore Pte Ltd., a wholly owned subsidiary of Merck & Co., Inc. (Whitehouse Station, NJ) dedicated an expansion of its production facilities in Singapore on July 28.
MSD Technology Singapore Pte Ltd., a wholly owned subsidiary of Merck & Co., Inc. (Whitehouse Station, NJ, www.merck.com) dedicated an expansion of its production facilities in Singapore on July 28. The expanded facilities are scheduled to open in the fourth quarter of 2006.
Now in the final stages of construction, the expansion consists of manufacturing formulation facilities and support infrastructure, and will increase capacity and production capability at the 49-acre site in Tuas Biomedical Park. The new SGD 100-million ($63 million) project brings Merck's overall investment in Singapore to more than SGD $1 billion ($633 million).
The expansion shares its Tuas Biomedical Park site with a bulk-pharmaceutical plant, which MSD opened in September 2001, and a formulation facility with more than 15,000 m2 of floor space, which opened in October 2003.
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
